|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM379937379 |
| 003 |
DE-627 |
| 005 |
20241112232524.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
241107s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1080/02664763.2024.2335569
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1598.xml
|
| 035 |
|
|
|a (DE-627)NLM379937379
|
| 035 |
|
|
|a (NLM)39507207
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Lee, Kwangmin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Estimation of world seroprevalence of SARS-CoV-2 antibodies
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 08.11.2024
|
| 500 |
|
|
|a published: Electronic-eCollection
|
| 500 |
|
|
|a Citation Status PubMed-not-MEDLINE
|
| 520 |
|
|
|a © 2024 Informa UK Limited, trading as Taylor & Francis Group.
|
| 520 |
|
|
|a In this paper, we estimate the seroprevalence against COVID-19 by country and derive the seroprevalence over the world. To estimate seroprevalence among adults, we use serological surveys (also called the serosurveys) conducted within each country. When the serosurveys are incorporated to estimate world seroprevalence, there are two issues. First, there are countries in which a serological survey has not been conducted. Second, the sample collection dates differ from country to country. We attempt to tackle these problems using the vaccination data, confirmed cases data, and national statistics. We construct Bayesian models to estimate the numbers of people who have antibodies produced by infection or vaccination separately. For the number of people with antibodies due to infection, we develop a hierarchical model for combining the information included in both confirmed cases data and national statistics. At the same time, we propose regression models to estimate missing values in the vaccination data. As of 31st of July 2021, using the proposed methods, we obtain the 95 % credible interval of the world seroprevalence as [ 35.5 % , 56.8 % ]
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Bayesian model
|
| 650 |
|
4 |
|a SARS-CoV-2 antibodies
|
| 650 |
|
4 |
|a hierarchical model
|
| 650 |
|
4 |
|a vaccination
|
| 650 |
|
4 |
|a world seroprevalence
|
| 700 |
1 |
|
|a Kim, Seongmin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jo, Seongil
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Jaeyong
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Journal of applied statistics
|d 1991
|g 51(2024), 15 vom: 06., Seite 3039-3058
|w (DE-627)NLM098188178
|x 0266-4763
|7 nnns
|
| 773 |
1 |
8 |
|g volume:51
|g year:2024
|g number:15
|g day:06
|g pages:3039-3058
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1080/02664763.2024.2335569
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 51
|j 2024
|e 15
|b 06
|h 3039-3058
|